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Abstract
Background: Nerve growth factor (NGF), glial cell line-derived neurotrophic factor (GDNF) and
brain-derived neurotrophic factor (BDNF) all play important roles in the development of the
peripheral sensory nervous system. Additionally, these growth factors are proposed to modulate
the properties of the sensory system in the adult under pathological conditions brought about by
nerve injury or inflammation. We have examined the effects of NGF, GDNF and BDNF on adult
rat trigeminal ganglion (TG) neurons in culture to gain a better understanding of how these growth
factors alter the cytochemical and functional phenotype of these neurons, with special attention to
properties associated with nociception.
Results: Compared with no growth factor controls, GDNF, at 1 and 100 ng/ml, significantly
increased by nearly 100% the number of neurons in culture at 5 days post-plating. A significant,
positive, linear trend of increasing neuron number as a function of BDNF concentration was
observed, also peaking at nearly 100%. NGF treatment was without effect. Chronic treatment with
NGF and GDNF significantly and concentration-dependently increased 100 nM capsaicin (CAP)-
evoked calcitonin gene-related peptide (CGRP) release, reaching approximately 300% at the
highest concentration tested (100 ng/ml). Also, NGF and GDNF each augmented anandamide
(AEA)- and arachidonyl-2-chloroethylamide (ACEA)-evoked CGRP release, while BDNF was
without effect. Utilizing immunohistochemistry to account for the proportions of TRPV1- or
CGRP-positive neurons under each growth factor treatment condition and then standardizing
evoked CGRP release to these proportions, we observed that NGF was much more effective in
enhancing CAP- and 50 mM K+-evoked CGRP release than was GDNF. Furthermore, NGF and
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increasing the Emax without altering the EC50 for either compound.
Conclusions: Taken together, our results illustrate that NGF, GDNF and BDNF differentially alter
TG sensory neuron survival, neurochemical properties and TRPV1-mediated neuropeptide release
in culture. In particular, our findings suggest that GDNF and NGF differentially modulate TRPV1-
mediated neuropeptide secretion sensitivity, with NGF having a much greater effect on a per
neuron basis than GDNF. These findings are discussed in relation to possible therapeutic roles for
growth factors or their modulators in pathological pain states, especially as these relate to the
trigeminal system.
Background
Among many trophic factors that act on sensory neurons,
three have been studied extensively: nerve growth factor
(NGF), glial cell line-derived neurotrophic factor (GDNF)
and brain-derived neurotrophic factor (BDNF). During
development, NGF, GDNF and BDNF, along with neuro-
trophin-3 (NT3), support the survival of subpopulations
of sensory neurons through their cognate trk receptors [1-
3]. In the adult, uninjured rat, receptors for NGF, GDNF
and BDNF are found in partially distinct subpopulations
of sensory neurons. NGF-responsive, trkA-containing
neurons are mostly small diameter, contain the neuropep-
tide calcitonin gene-related peptide (CGRP), and are gen-
erally thought to have nociceptive properties [4,5]. The
BDNF-responsive, trkB-containing population of sensory
neurons is predominantly larger diameter and mechano-
sensitive [6], although there is considerable overlap with
the trkA population [7]. GDNF receptors are more wide-
spread, with as many as 60% of dorsal root ganglion
(DRG) neurons containing c-ret, while GFR components
are found throughout the c-ret population, as well as in c-
ret negative neurons [8,9]. Additionally, sensory neurons
that are postnatally dependent on GDNF for survival bind
the isolectin B4 (IB4, [2]).
NGF is thought to play a primary role in the development
and maintenance of several pro-algesic states. NGF pro-
duces sensitization of nociceptive responses in vivo and
increases responsiveness to chemical stimuli associated
with nociceptive neurotransmission in vitro [10-12]. NGF
increases the expression of the pro-inflammatory neu-
ropeptide CGRP [13] and increases substance P (SP) and
CGRP content in sensory neurons [14-17]. NGF also pro-
motes the development and maintenance of hyperalgesia
following chronic constriction injury [18,19]. Addition-
ally, NGF increases capsaicin (CAP) sensitivity both in
vivo and in vitro [20-24]. In accordance with this
increased CAP sensitivity, NGF increases the expression of
the CAP- and noxious heat-sensitive ion channel vanilloid
receptor type 1 (TRPV1) through the ras/p38 MAP kinase
signaling pathway, thereby promoting thermal hyperalge-
sia [25,26]. Additionally, NGF has recently been shown to
modulate TRPV1 by releasing the receptor from phospho-
tidylinositol-4,5-bisphosphate-mediated inhibition [27].
GDNF also plays a role in modulating nociceptive
processing, but with contrasting in vitro and in vivo
effects. In cultured DRG neurons, GDNF increases CAP
sensitivity and TRPV1 expression [16,26] and increases
neuropeptide content [16]. On the other hand, intrathecal
injection of GDNF has no effect on C-fiber evoked out-
flow of SP and does not induce thermal hyperalgesia,
while NGF does both [15]. This, coupled with the obser-
vation that GDNF-overexpressing mice do not develop
thermal or mechanical hypersensitivity [28], suggests that
GDNF might not lead to nociceptor sensitization in vivo.
In fact, in nerve injured rats, GDNF has antihyperalgesic
effects [29] and promotes the functional regeneration of
DRG-spinal cord connections [30]. It is not understood
how this dissociation of the in vitro and in vivo effects of
GDNF is manifested.
Inflammation and nerve injury both increase BDNF con-
tent in DRG neurons and in the spinal cord, and this
increase in BDNF is associated with the maintenance of a
hyperalgesic state [31-36]. Furthermore, BDNF is released
in the spinal cord upon noxious afferent stimulation
[37,38], and peripheral CAP application increases BDNF
release at central terminals of sensory neurons [39].
Hence, BDNF might act as a neurotransmitter in the pain
pathway in adult animals [40]. The trophic properties of
BDNF on adult sensory neurons, particularly nociceptors,
are poorly understood.
In addition to CAP, a number of other TRPV1 agonists
have been described. Among these are compounds that
are also cannabinoid receptor agonists, including the
endogenous cannabinoid anandamide (AEA, [41,42] and
the synthetic AEA analogue arachidonyl-2-chloroethyla-
mide (ACEA, [43]). AEA causes antinociception in vivo
through central [44] and peripheral mechanisms [45,46].
It is not known, though, whether the endogenous produc-
tion of AEA can reach sufficient concentrations under
pathophysiological states to act as an endogenous activa-
tor of TRPV1. One potential mechanism whereby growthPage 2 of 15
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sensitization is through the modulation of the efficacy or
potency of AEA at TRPV1.Thus, growth factors might
unmask conditions under which AEA could be capable of
functioning as an endogenously produced TRPV1 agonist,
potentially leading to neurogenic inflammation and ther-
mal hyperalgesia.
The aim of the present work was to gain a more precise
understanding of NGF-, GDNF- and BDNF-dependent
alterations of cultured TG sensory neuron survival and
phenotype, with attention to markers and functions that
are related to nociception. Furthermore, by relating these
findings to neurosecretion associated with pharmacologi-
cal stimulation of TRPV1, we hope to present a rationale
for differences in how these neurotrophins might contrib-
ute to altered nociception at the level of the TG sensory
neuron. Moreover, there is a gap in knowledge concerning
neurotrophic factor influence over TG neurons, as the vast
majority of our understanding of how neurotrophins alter
sensory neurons stems from studies of the DRG. The
recent advances of CGRP receptor antagonists for the
treatment of migraine [47,48] raises the possibility that
manipulations which influence CGRP expression and/or
secretion might be beneficial in the treatment of migraine
or conditions related to the cerebral vasculature. A fuller
understanding of the impact of NGF, GDNF and BDNF on
TG neurochemical properties has the potential to lead to
novel therapeutic strategies concerning disease states
involving neuropeptide secretion in the trigeminal sys-
tem, such as migraine.
Results
Effects of NGF, GDNF or BDNF treatment on neuronal 
survival in vitro
TG neuronal cultures were plated at equal densities
(~5000 neurons / well) on 8-well culture slides (experi-
mental design shown in Figure 1). After five days of
growth factor treatment, immunocytochemistry (ICC) for
200 kD neurofilament (NF-H) present in all sensory neu-
rons [49] and not other ganglion cells (i.e., glia), was per-
formed to determine the number of neurons in each well.
Representative photomicrographs are shown in Figure 2.
NGF did not significantly influence the number of neu-
rons in culture following five days of treatment (Fig 3).
On the other hand, GDNF significantly enhanced the
number of neurons per well versus no growth factor
treated cultures at both 1 and 100 ng/ml (Fig. 3). The
Experimental design for neuronal countingFigu e 1
Experimental design for neuronal counting. 12 slides were utilized in these experiments, with 4 slides for each growth factor. The 
antibodies used on each slide are shown to the right of the slide along with the wavelength for the corresponding secondary 
antibody. For the 2 matching wells for each slide (growth factor concentration), the neuron numbers were averaged to give 
one observation (since the wells were not derived from independent cultures). Each slide contained a no growth factor control 
(blue), hence n = 9 for this condition. All other growth factors at 1 (i.e. NGF, red), 10 (i.e. GDNF, green) or 100 ng/ml (i.e. 
BDNF, yellow) are n = 3. The same slides were then utilized to ascertain the proportions of neurons expressing CGRP- or 
TRPV1-immunoreactivity or IB4-binding, as described in Methods. This figure refers to Figures 2 and 3 and Table 1.Page 3 of 15
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sic, as 10 ng/ml GDNF did not significantly enhance neu-
ronal survival. It should be noted that in GDNF-treated
cultures we observed a robust sprouting of TG neurons,
appearing far more robust than in NGF- or BDNF-treated
cultures (although sprouting was still evident in these
cultures).
Effects of NGF, GDNF or BDNF treatment on TRPV1 
mRNA and protein levels
To directly assess changes in TRPV1 mRNA levels with
growth factor treatment, quantitative, realtime PCR was
conducted. NGF, GDNF or BDNF (100 ng/ml) did not sig-
nificantly alter TRPV1 mRNA levels after 5 days of treat-
ment (Fig. 4). To evaluate whether growth factor
treatment might exert post-transcriptional regulation of
TRPV1 gene expression, we next examined their effects on
TRPV1 protein levels by Western blot. As shown in Fig. 5,
a major band was detected with the TRPV1 antibody at
~130 kD, consistent with the glycosylated form of TRPV1
[25]. NGF and GDNF (100 ng/ml) each was demon-
Representative 20X photomicrographs of growth factor-tr at d TG neuronsFigure 2
Representative 20X photomicrographs of growth factor-treated 
TG neurons. TG cultures were fixed and labeled for NF-H-
immunoreactivity (green), and the 20X photomicrographs 
depicted here are representative of the 20 images taken per 
slide for each condition for neuron counting. The upper 
frame shows the no growth factor treated control with cor-
responding growth factor treatments shown for BDNF, 
GDNF and NGF at 1, 10 and 100 ng/ml concentrations.
NGF, GDNF and BDNF and TG neuronal surivalFigure 3
NGF, GDNF and BDNF and TG neuronal surival. All NF-H-
immunoreactive neurons were counted for each growth fac-
tor-treated TG culture (n = 9 no growth factor; n = 3 all 
other conditions) and compared with the control (no growth 
factor-treated) TG cultures to assess neuronal survival at day 
5 post-plating (* p < 0.05, *** p < 0.001).
Assessment of TRPV1 mRNA levels by Realtime PCRFigure 4
Assessment of TRPV1 mRNA levels by Realtime PCR. Levels of 
TRPV1 mRNA are depicted as fold change compared with no 
growth factor-treated cultures for each growth factor condi-
tion normalized to its corresponding GAPDH mRNA levels 
(n = 3).Page 4 of 15
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imately 50% compared with no growth factor-treated
cultures (Fig 5). BDNF effects on TRPV1 protein levels
were not assessed, because preliminary studies indicated
that BDNF did not influence CAP-evoked CGRP release.
Effects of NGF, GDNF or BDNF treatment on K+-evoked 
CGRP release and CGRP content
We next examined the effect of growth factor treatment on
K+-evoked CGRP release and total CGRP content in TG
neuronal cultures. NGF treatment significantly and con-
centration-dependently increased 50 mM K+-evoked
CGRP release at every concentration, peaking (10.5-fold
increase vs. control) at 100 ng/ml (Fig. 6A). Similarly,
GDNF significantly and concentration-dependently
increased K+- evoked release at every concentration, again
peaking (9.7-fold increase vs. control) at 100 ng/ml. On
the other hand, BDNF did not alter K -evoked CGRP
release.
Because there were differences in neuron numbers
between growth factor conditions, we examined under
each condition the proportion of neurons that were posi-
tive for CGRP, TRPV1 or IB4. Representative photomicro-
graphs for each of these conditions are shown in Figure 7.
The proportion of neurons positive for CGRP, TRPV1 or
IB4 are shown in Table 1. In no cases were CGRP- or
TRPV1-immunoreactive or IB4-binding neurons not like-
wise immunoreactive for NF-H. We then utilized the pro-
portion of CGRP-expressing neurons under NGF, GDNF
Assessment of TRPV1 protein by Western BlotFigure 5
Assessment of TRPV1 protein by Western Blot. Panel A, 20 µg 
total protein was electrophoretically seperated per lane and 
transferred to membranes that were subsequently probed 
with an anti-TRPV1 antibody and then reprobed for stand-
ardization with β-actin (X = no growth factor; N 100 = NGF 
100 ng/ml; G 100 = GDNF 100 ng/ml). Image is of a repre-
sentative Western blot. Immunoreactivity to a protein corre-
sponding to the size of the glycosyated form of TRPV1 was 
detected at ~130 kD. Panel B depicts alterations in TRPV1 
protein levels standardized to β-actin (* p < 0.05, n = 3)
50 mM K+ -evoked CGRP release and total CGRP content in TG culturesFigure 6
50 mM K+ -evoked CGRP release and total CGRP content in TG 
cultures. Panel A illustrates the effect of growth factor treat-
ment on 50 mM K+ -evoked CGRP release, while panel B 
shows the data standardized to the number of CGRP-posi-
tive neurons per condition as a proportion of the no growth 
factor-treated cultures. Panel C shows total CGRP content 
by growth factor treatment, and again, panel D shows this 
data standardized to CGRP-positive neurons, as stated above 
(*** p < 0.001, n = 6).Page 5 of 15
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CGRP release to the number of CGRP-immunoreactive
neurons under each condition, respectively (see Methods
for normalization calculation). Following this transfor-
mation, NGF treatment still augmented K+-evoked CGRP
release at every concentration tested, with the magnitude
of the effect reaching 18 times that of control (Fig 6B).
While GDNF treatment again enhanced K+-evoked CGRP
release at all concentrations following normalization, its
peak effect was relatively lower. BDNF treatment contin-
ued not to have an effect following normalization to the
number of CGRP-immunoreactive neurons.
Much like K+-evoked CGRP release, total CGRP content
was increased significantly by NGF and GDNF treatment,
while BDNF had no effect (Fig. 6C). Both NGF and GDNF
increased CGRP content concentration-dependently at
every concentration (p < 0.001), with peaks at 10 ng/ml
(3.2-fold increase) for NGF and 100 ng/ml (3.0-fold
increase) for GDNF (Fig. 6C). Again, we normalized these
data to CGRP-immunoreactive neurons to assess changes
in relation to alterations in CGRP-immunoreactive neu-
rons between the growth factor conditions. Interestingly,
the GDNF augmentation of CGRP release appeared to be
due primarily to the large increases in neuron survival,
because only the 10 ng/ml GDNF condition was signifi-
cantly greater than control (p < 0.001), but still substan-
tial lower compared with the untransformed lysis figures
(Fig. 6D). On the other hand, normalization led to a fur-
ther augmention in the effect of NGF on total CGRP con-
tent, up to a 5.8-fold increase. BDNF treatment did not
alter the normalized CGRP content.
Effects of NGF, GDNF or BDNF treatment on CAP-evoked 
CGRP release
To assess the effect of growth factor supplementation on
the neurosecretory function of nociceptors in culture, we
evaluated CAP-evoked CGRP release. Treatment with 100
nM CAP for 10 min led to a significant enhancement of
CGRP release over baseline under all conditions. Treat-
ment of cultures with NGF or GDNF resulted in a concen-
tration-dependent enhancement of this effect, with
significant increases in CAP-evoked CGRP release at 1, 10
and 100 ng/ml. BDNF also enhanced the ability of CAP to
evoke CGRP release; however, the effect was only seen at
the 100 ng/ml concentration. In every case, GDNF and
NGF (except 1 ng/ml NGF) supplementation significantly
Table 1: Percentage of neurons expressing markers.
X N1 N10 N100 G1 G10 G100 B1 B10 B100
TRPV1 37.9 37.5 37.4 40.0 48.4 57.5 66.6 50.1 50.9 47.8
CGRP 67.1 61.4 61.0 54.3 64.6 74.4 76.0 65.0 68.7 63.5
IB4 56.5 61.3 73.1 62.0 63.3 65.0 63.9 59.6 61.8 47.2
The percentage of total NF-H-positive neurons expressing TRPV1, CGRP or IB4 is shown for each growth factor condition (X: no growth factor, N: 
NGF, G: GDNF, B: BDNF).
Representative 20X photomicropgraphs of colocalization of sensory eurons markers with NF-H in growth f ctor-tr at d TG neuronsFigure 7
Representative 20X photomicropgraphs of colocalization of sen-
sory neurons markers with NF-H in growth factor-treated TG neu-
rons. Immunoreactivity for CGRP and TRPV1 and staining for 
IB4-binding sites (red) was assessed following immunocyto-
chemistry for NF-H (green) to assess the proportion of neu-
rons expressing these population markers. Representative 
20X photomicrographs of each growth factor at 100 ng/ml 
for CGRP (left), TRPV1 (middle) and IB4 (right) are shown as 
well as control (no growth factor-treated) TG cultures (top 
panels). All cell bodies containing both NF-H-immunoreactiv-
ity and CGRP- or TRPV1-immunoreactivity or IB4-binding 
appear yellow from the overlay of the red with green. In no 
cases were neurons observed that contained CGRP- or 
TRPV1-immunoreactivity or IB4-binding without the co-pres-
ence of NF-H-immunoreactivity.Page 6 of 15
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centration of BDNF (Fig 8A).
To determine to what extent the enhancement of CAP-
evoked CGRP release in response to growth factor treat-
ment might derive from increased neuronal survival and/
or up-regulation in the proportion of neurons expressing
TRPV1, release data were normalized to the number of
TRPV1-immunoreactive neurons (Fig. 8B; TRPV1 neuron
proportions shown in Table 1). In this case, NGF treat-
ment still significantly increased CAP-evoked CGRP
release over no growth factor treatment at 1, 10 and 100
ng/ml. However, this normalization procedure led to a
relative reduction in the GDNF effect on CAP-evoked
CGRP release, such that only the 10 ng/ml condition
reached a significant increase in CGRP outflow. After nor-
malization, BDNF treatment had no significant effect on
CAP-evoked CGRP release at 1 or 100 ng/ml and actually
reduced the amount of release at 10 ng/ml. Moreover, fol-
lowing normalization, NGF-treated neurons displayed a
significantly higher CGRP release than either GDNF- or
BDNF-treated neurons at every concentration of growth
factor tested (Fig 8B).
Because treatment with either GDNF or NGF induced a
large increase in 100 nM CAP-evoked CGRP release, we
assessed the effect of supplementation with these growth
factors on the receptor pharmacodynamics of this
response compared with no growth factor supplementa-
tion. GDNF or NGF treatment significantly increased the
Hill slope of the concentration-response function from
1.12 ± 0.47 in the no growth factor condition to 3.760 ±
0.057 for 100 ng/ml NGF and to 4.48 ± 0.90 for 100 ng/
ml GDNF (Fig 9A) but had no effect on the EC50 (41 nM
for GDNF or NGF and 47 nM for no growth factor).
GDNF (100 ng/ml) or NGF (100 ng/ml) treatment caused
a significant, five-fold increase in the Emax of the CAP con-
centration-response curve (Fig. 9B). A common feature of
CAP concentration-response functions is that they fre-
quently exhibit an inverted U-shape, likely attributable to
TRPV1 desensitization at higher concentrations. Thus,
whereas the concentration-response function in the
absence of growth factor displayed desensitization only at
1 uM, that for either GDNF- and NGF-treated TG cultures
showed desensitization of the CAP-evoked CGRP
response at concentrations above 100 nM (Fig. 9B).
Effects of NGF, GDNF or BDNF treatment on AEA- and 
ACEA-evoked CGRP release
To test whether growth factor-mediated enhancement of
neuropeptide release might be generalizable to other
TRPV1 secretagogues, we evaluated the dual cannabinoid-
vanilloid agonists AEA and ACEA. As in the case with CAP,
the effects of AEA and ACEA on evoked CGRP release were
augmented by supplementation of TG cultures with NGF
Growth factor treatment increases CAP (100 nM)-evoked CGRP release in TG culturesFigure 8
Growth factor treatment increases CAP (100 nM)-evoked CGRP 
release in TG cultures. Panel A illustrates the total amount of 
CGRP released by 10 min treatment with capsaicin for each 
growth factor. Panel B illustrates the same data standardized 
to the number of TRPV1-positive neurons under each 
growth factor condition (** p < 0.01, *** p < 0.01 for com-
parisons to no growth factor treated controls; ## p < 0.01, 
### p < 0.001 for comparisons to NGF at the equivalent 
growth factor concentration by two-way ANOVA with Bon-
ferroni post-test; n = 6).Page 7 of 15
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treated with growth factors were largely unresponsive to
AEA or ACEA, in terms of CGRP release, treatment of cul-
tures with either NGF or GDNF for 5 days at 1, 10 or 100
ng/ml caused a concentration-dependent increase in
CGRP release evoked by 30 µM AEA or ACEA. Further-
more, the estimated EC50 values for each of the individual
growth factors to increase evoked CGRP release were
equivalent for CAP, AEA and ACEA (NGF = 3.5 ng/ml;
GDNF = 1.3 ng/ml). In contrast, BDNF supplementation
did not augment AEA- or ACEA-evoked CGRP release,
while a small, yet significant, increase in CAP-evoked
CGRP release was observed with increasing BDNF concen-
tration (Fig. 10C). When TG neurons were supplemented
with either 100 ng/ml NGF or GDNF, the Emax and EC50
values for AEA did not change (F = 2.082(4,85)) ; however,
when compared with non-growth factor-treated TG neu-
rons, the Emax was significantly augmented (Fig. 10D).
Discussion
This study demonstrates that NGF, GDNF and BDNF dif-
ferentially influence neuronal survival, neuropeptide con-
tent and stimulated secretion of TG neurons in culture.
GDNF significantly augments TG neuronal survival, while
both NGF and GDNF modulate CAP sensitivity, and alter
the pharmacodynamics of the concentration-response
function for CAP-evoked CGRP release. Furthermore,
NGF and GDNF increased the releasable pool and total
content of CGRP while increasing TRPV1 protein, without
increasing its mRNA. These data support the hypothesis
that GDNF and NGF, but not BDNF, alter CAP sensitivity
in cultured TG neurons, and taken together, suggest that
the differential effects of NGF and GDNF in vitro may
reflect their differential effects in vivo, particularly with
regard to TRPV1-mediated nociception.
NGF and GDNF alter capsaicin-evoked CGRP releaseFigure 9
NGF and GDNF alter capsaicin-evoked CGRP release. Concen-
tration-response functions (molar, log units) are shown for 
capsaicin-evoked CGRP release in TG cultures maintained in 
100 ng/ml NGF, 100 ng/ml GNDF or no growth factor condi-
tions (n = 6). Panel A illustrates the maximum relative effect 
of capsaicin under each condition matched to the maximum 
evoked-CGRP release for that given condition. Panel B 
depicts the CAP-evoked CGRP release data in terms of 
CGRP released in fmoles in the presence or absence of NGF 
or GDNF to illustrate the magnitude of increases in Emax and 
the biphasic nature of the capsaicin-evoked CGRP concen-
tration-response function.
The effect of growth factor treatment on AEA- and ACEA-evok d CGRP releaseFigure 10
The effect of growth factor treatment on AEA- and ACEA-evoked 
CGRP release. TG neurons were grown in the presence of the 
indicated concentrations of NGF (panel A), GDNF (panel B) 
or BDNF (panel C) for five days and then exposed to 100 nM 
CAP, 30 µM AEA or 30 µM ACEA for 10 min, and the 
released CGRP was quantified (n = 12). Panel D, TG neurons 
were grown in the absence of growth factors or in the pres-
ence of 100 ng/ml NGF or GDNF for 5 days and exposed to 
the indicated concentrations of AEA (molar, log units) to 
assess CGRP release (### p < 0.001; GDNF and NGF vs. no 
growth factor; two-way ANOVA, Bonferroni post-test, n = 
6).Page 8 of 15
(page number not for citation purposes)
BMC Neuroscience 2005, 6:4 http://www.biomedcentral.com/1471-2202/6/4GDNF, but not NGF or BDNF significantly increased the
number of neurons present in TG culture 5 days post-plat-
ing. The finding that this effect of GDNF was biphasic, as
the 10 ng/ml concentration did not enhance the number
of neurons in TG culture, suggests the possible involve-
ment of different receptors with different concentrations
of GDNF. Multiple receptors exist in the GDNF receptor
family, and they function in concert with the protein c-ret.
GDNF binds most readily to GFR alpha-1, but also binds
to GFR alpha-2 / c-ret heterodimers [50]. GFR alpha-1 and
-2 are expressed in sensory ganglia and are found mostly
in IB4-binding neurons [51] that also contain c-ret [8].
Notably, it has been suggested that GFR alpha-1 and GFR
alpha-2-containing neurons in the adult rat make up two
distinct populations in the DRG within the IB4-binding
class [8]; hence, the effects observed here may be due to
GDNF acting through its high affinity GFR alpha-1 site at
the 1 ng/ml concentration and through either or both
GFR alpha-1 and GFR alpha-2 / c-ret, for which it has a
lower affinity, at the 100 ng/ml concentration. While the
observation here that GDNF promotes survival is a novel
finding for rat TG sensory neurons in primary culture, the
neuroprotective effects of GDNF are well documented.
GDNF is protective against the loss of dopaminergic neu-
rons in animal models of Parkinson's disease [52,53], and
GDNF reduces the number of apoptotic bodies in DRG
explants from adult mice [54]. GDNF also rescues the
reduction of P2X3 expression that occurs in the DRG fol-
lowing axotomy [55].
Although BDNF and NGF did not significantly increase
the number of TG neurons in culture, we did observe a
significant, linear trend for increased neuron survival as a
function of increasing BDNF concentrations, an observa-
tion not present in NGF-treated TG cultures. Hence, BDNF
and GDNF both promoted the survival of TG neurons in
vitro. Primary cultures generated here were grown in the
presence of mitotic inhibitors, which greatly reduce the
supportive glial cells and the trophic factors they normally
provide TG neurons in the native ganglia (although some
of these cells are still present). Removal of astroglial sup-
port promotes apoptosis in cerebral neuronal cultures, an
effect which is reversed by addition of GDNF or BDNF,
but not NGF, to the culture medium [56]. The addition of
GDNF or BDNF to the culture medium here may have re-
supplied, at least partially, the withdrawn glial-supplied
trophic factors that maintain sensory neurons in vivo,
thereby increasing the number of neurons in culture at 5
days. It should be noted, however, that despite the signif-
icant effects of the growth factors observed in this study
on neuronal survival, from an original density of nearly
5,000 neurons / well in the original culture homogenate,
only about 10% of neurons could be counted at 5 days
post-platting, in the control condition. A maximum of
just over 20% were counted in the 100 ng/ml GDNF
treated TG cultures. Therefore, it stands to reason that
GDNF and BDNF are supporting the survival of certain
classes of sensory neurons that are not supported either
without growth factors or with NGF alone.
The proportions of TG neurons in culture that expressed
CGRP- or TRPV1-immunoreactivity or IB4-binding sites
were assessed with attention to how these proportions
changed in the presence of NGF, GDNF and BDNF. Nota-
bly, the proportion of sensory neurons in vitro that
expressed CGRP (~65%) was much larger than the known
proportion of CGRP-containing neurons in native TG
(~35%, [57]). This likely indicates that the culturing
process conditions are either selectively preserving pepti-
dergic neurons or that normally non-peptidergic neurons
novelly express CGRP in culture. On the other hand, dis-
crepancies on reports of the percentage of IB4-binding
neurons in native TG, ranging from ~35–60% [58,59]
make it difficult to assess whether there is an increased
proportion of IB4-binding neurons in culture; however,
our data indicate that this proportion is at least in the
upper range, if not greater than native TG. Furthermore, a
probable significant overlap exists between CGRP-
immunoreactive and IB4-binding neuronal populations
observed here, as both were found in the majority of TG
neurons in culture, in agreement with the demonstration
that these populations overlap significantly in native,
adult rat TG and DRG (Price and Flores, unpublished
observations).
We observed that a greater proportion of TRPV1-immuno-
reactive neurons were present with GDNF supplementa-
tion (nearly 30% increase), again indicating either that
GDNF preferentially supports the survival of TRPV1-
expressing sensory neurons or that neurons that do not
normally express TRPV1 begin expressing TRPV1 when
GDNF is included in the culture medium. The latter prop-
osition is supported by the finding that peripheral treat-
ment with anti-GDNF antibodies suppresses the novel
expression of TRPV1 in IB4-binding neurons following
peripheral inflammation [60]. The percentage of TRPV1-
expressing neurons in TG cultures not treated with growth
factors was essentially equivalent to the percentage in
native TG [57]. This finding indicates that, not only does
GDNF promote survival of TG neurons in culture, but also
enriches for TRPV1-expressing neurons, suggesting that
GDNF might be preferentially neuroprotective for sensory
neurons in adult animals that express TRPV1.
We have also illustrated that chronic application of NGF
or GDNF, but not BDNF (except at high concentrations,
and to a much lesser degree), increases CAP-evoked CGRP
release from TG neurons in vitro. NGF and GDNF each
increased TRPV1 protein, and both upregulated the CGRP
content of TG neurons. Both the NGF- and GDNF-Page 9 of 15
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ally regulated, as neither of these growth factors altered
TRPV1 mRNA levels. NGF, in the setting of inflammation,
is known to increase TRPV1 protein, but not mRNA,
through activation of the p38/MAP kinase pathway
[25,26], and NGF-mediated upregulation of TRPV1 is
blocked by over-expression of dominant-negative ras
[26]. Interestingly, the study by Bron et al. (2003) indi-
cated that GDNF is also able to upregulate TRPV1 expres-
sion; although this conclusion was based on
immunofluorescence and cobalt uptake assays, it is con-
sistent with our direct demonstration of GDNF-induced
upregulation of TRPV1 protein by Western blot. After nor-
malization to the number of neurons that express TRPV1
and CGRP, we found that NGF had a much greater effect
on CAP-evoked CGRP release and neuropeptide content,
on a per cell basis, than did GDNF. On the other hand,
GDNF increased the proportion of neurons in culture that
express TRPV1, such that GDNF-maintained cultures con-
tained a higher number of TRPV1-expressing neurons
compared with NGF-maintained cultures. Hence, our
findings suggest that NGF increases CAP responsiveness in
individual cultured TG neurons. On the other hand,
GDNF appears to increase the responsiveness of the in
vitro population by altering the proportion of TRPV1 neu-
rons and upregulating the releasable pool of CGRP, as evi-
denced by the persistent increase in 50 mM K+-evoked
CGRP release after normalization. This difference in the
ability of GDNF and NGF to enhance individual neuronal
neuropeptide content and CAP responsiveness could par-
tially explain why NGF induces hyperalgesia
[10,12,19,61] while GDNF does not [15,28,29]. Our find-
ings suggest that while GDNF might play a role in main-
taining CAP sensitivity in vitro, its effects in vivo might be
of a preservative nature that prevents the development of
pain exacerbation following experimental manipulation.
Furthermore, NGF and GDNF might differentially/pre-
dominantly subserve two of the main physiologic proc-
esses following injury: hyperalgesia to protect the
organism from further injury (NGF) and regeneration/
repair to restore function (GDNF).
While it has been shown, using a variety of dependent
measures, that both NGF and GDNF increase CAP respon-
siveness [16,17], this is the first demonstration that these
growth factors qualitatively alter the pharmacodynamics
of the neuronal response to CAP in TG neurons. The
increase in the Hill slope of the CAP response following
exposure to NGF or GDNF indicates that these growth fac-
tors induce positive cooperativity, possible at the level of
TRPV1. While the mechanism underlying this effect is not
known, it could involve an alteration in post-translational
modifications and/or protein interactions of TRPV1 in
response to NGF or GDNF. NGF or GDNF also decreased
the concentration of CAP necessary to induce tachyphy-
laxsis compared with control cultures. These findings
indicate that TRPV1-mediated sensory neuron desensiti-
zation might be a more efficacious therapeutic strategy in
pathologies known to be associated with increased levels
of NGF and/or GDNF. While we are unaware of any data
linking GDNF with migraine, increased cerebrospinal
fluid levels of NGF are associated with chronic headache
[62]. Interestingly, a TRPV1 targeted approach has been
utilized in a clinical trial for migraine treatment in which
intranasal civamide (a TRPV1 agonist) was shown to be
effective for acute treatment of migraine [63], indicating
that TRPV1 agonists might be employed in this condition,
possibly to desensitize CGRP-containing TG nerve
endings.
Similarly to CAP-evoked CGRP release, the ability of AEA
and ACEA to evoke release was concentration-depend-
ently augmented by NGF or GDNF supplementation but
was unaltered by BDNF. Moreover, the respective poten-
cies of NGF and GDNF to enhance the CGRP release in
response to CAP, AEA and ACEA were equivalent. This
suggests that the pharmacology of CAP, AEA and ACEA at
TRPV1, at least with respect to neuropeptide secretion, is
similarly regulated in the presence of either of these
growth factors. Insofar as NGF and GDNF have been
implicated in the development of nociceptor sensitization
in a number of pathological states, it should be consid-
ered that endocanninoids are apt to have enhanced
TRPV1-mediated peripheral neuromodulatory effects
under these conditions.
Conclusions
Taken together, our results illustrate that NGF, GDNF and
BDNF differentially alter sensory neuron survival, neuro-
chemical properties and TRPV1-mediated neuropeptide
release of TG neurons in culture. GDNF and, to a lesser
extent, BDNF promote survival of TG neurons and GDNF
enhances the proportion of neurons that exhibit TRPV1-
immunoreactivity. GDNF or NGF enhanced CAP-, AEA-
and ACEA-evoked CGRP release from TG neurons in vitro
and increased TRPV1 protein, likely through translational
regulation, and overall CGRP content. On the other hand,
our findings suggest that GDNF and NGF differentially
modulate TRPV1-mediated neuropeptide secretion
sensitivity, with NGF having a much greater effect on a per
neuron basis, providing a possible explanation for why
NGF promotes thermal hypersensitivity in vivo while
GDNF apparently does not. Although the present studies
were conducted on cultured neurons under artificially
controlled conditions, these findings contribute to a
growing body of work concerning neurotrophin modula-
tion of the properties of nociceptors. Thus the results
described here have implications for advancing our
understanding of how this system might be advanta-Page 10 of 15
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mide) was from Fluka-Aldrich (St Louis, MO). AEA (N-(2-
hydroxyethyl)-5Z,8Z,11Z,14Z-eicosatetraenamide, in
water soluble emulsion), and ACEA (N-(2-chloroethyl)-
5Z,11Z,14Z)-eicosatetraenamide were from Tocris (Ellis-
ville, MO). Recombinant rat GDNF and recombinant
human (100% homologous to rat) BDNF were from
Sigma (St Louis, MO). Rat NGF was from Harlan (Indian-
apolis, IN). All other chemicals were from Sigma, unless
otherwise stated.
TG culture
Adult, male Sprague-Dawley rats weighing 250–300 g
were used in this study. All procedures utilizing animals
were approved by the Institutional Animal Care and Use
Committee of The University of Texas Health Science
Center at San Antonio and were conducted in accordance
with policies for the ethical treatment of animals estab-
lished by the National Institutes of Health. Animals were
euthanized by decapitation and their TGs were rapidly
dissected (~30 s) and placed in ice-cold Ca++- and Mg++-
free Hank's balanced salt solution (HBSS, Gibco,
Carlsbad, CA). TGs were enzymaticaly digested for 30 min
with 5 mg/ml collagenase followed by 25 min with 0.1%
trypsin type IX supplemented for the last 10 min with 10
units of DNase I (Roche, Indianapolis, IN). TG cell sus-
pensions were then centrifuged at 2000 RPM for 2 min,
vortexed briefly and centrifuged again. They were then
resuspended in basal culture medium containing high
glucose Dulbeco's Modified Eagle's Medium (DMEM,
Gibco), 1X pen-strep (Gibco), 1X glutamine (Gibco) and
3 µg/mL 5-FDU and 7 µg/mL uridine as mitotic inhibi-
tors. TG cell suspensions were gently triturated with a Pas-
teur pipette followed by successive triturations through
19- and 23-gauge needles. TG cell suspensions were then
transferred to a separate container and adjusted to the
total volume needed for plating at a density of ~5000 neu-
rons / well. The appropriate growth factors were added to
this suspension prior to plating.
Immunocytochemistry (ICC) and Image Aquisition
TG cultures were first washed in PBS and fixed for 1 hr in
3.7% formaldehyde in PBS. Next, TG cultures were
washed 3 times in PBS and permeabilized in PBS contain-
ing 10% normal goat serum (NGS, Gibco) and 0.2% Tri-
ton X-100 (Sigma) for 1 hr. Finally, TG cultures were
blocked 3 × 10 min in PBS containing 10% NGS and then
exposed to NF-H mouse-monoclonal antibody (1:300;
Sigma) overnight at 4°C. Primary antisera were then
washed off and goat anti-mouse Alexa-Fluor-488 (1:300,
Molecular Probes, Eugene, OR), or goat anti-mouse Alexa-
Fluor-594 (1:300) was applied for 1 hr at room tempera-
ture. For double-labeling either CGRP rabbit polyclonal
(1:750, Peninsula Labs) or TRPV1 guinea pig polyclonal
(1:3000, Neuromics) or IB4-conjugated to Alexa-Fluor-
488 (1:1000, Molecular Probes) was then added
overnight at 4°C. CGRP or TRPV1 antisera were followed
by goat anti-rabbit Alexa-Fluor-594 (1:300) for 1 hr at
room temperature. All images were acquired using a
Nikon E600 microscope (Melville, NY) equipped with a
Photometrics SenSys digital CCD camera (Roper Scien-
tific, Tucson, AZ) connected to a computer equipped with
Metamorph V4.1 image analysis software (Universal
Image Corporation, Downingtown, PA). Twenty 20X
images were taken of each well to capture the complete
cellular area for neuron counts. For these experiments, all
neurons displaying fluorescent signal above background
were counted as positive for the specific marker. This was
defined by scaling the image, using Metamorph's built-in
scaling feature, to an average pixel value for negative neu-
rons in the case of TRPV1, CGRP and IB4 (no scaling was
performed for NF-H ICC) and establishing all neurons as
positive that were above that threshold. For double labe-
ling experiments, the thresholded images were then over-
laid and analyzed for the presence of both signals to assess
colocalization.
Neuronal Counting (Survival)
TG cell suspensions (~5000 neurons/well) were added to
8-well poly-D-lysine Lab-Tek II chamber slides (Nalge/
Nunc, Naperville, IL). Neuron density for plating was
determined by counting neurons with a hemacytometer
with Neubauer rulings and the cultures for each slide were
generated independently. Neurons were easily distin-
guished from other cell types for plating density measure-
ments due to their large size and opaqueness. Medium
was changed after 24 hr and 72 hr, and on day 5, ICC was
performed (as described above). In total, 12 chamber
slides were utilized. The experimental design is shown in
figure 1 with 4 slides each for NGF, GDNF and BDNF.
Neurons on the NF-H alone slides were not counted as
these slides were used only for images shown in figure 2.
To assess neuronal survival, all NF-H- immunoreactive
neurons were counted for each growth factor concentra-
tion and are presented as mean ± SEM. The 2 matching
wells for each slide were averaged and this average was
used for 1 observation (as described in Fig 1). For colocal-
ization studies, the previously generated NF-H-immuno-
reactive neuron counts for each well were followed by
counting of CGRP- or TRPV1-immunoreactive or IB4-
binding neurons in the same wells to generate the propor-
tion of neurons expressing these markers. The total for the
2 matching wells were summed to yield the final propor-
tion. At least 500 NF-H-immunoreactive neurons were
counted under every growth factor condition to calculatePage 11 of 15
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examined. In no cases were CGRP-, TRPV1- or IB4-binding
neurons not likewise positive for NF-H. Colocalization is
presented only as an overall percentage.
Realtime PCR
TG cultures were prepared on 48-well poly-D-lysine pre-
coated plates (Becton Dickinson, Franklin Lakes, NJ) at an
initial density of ~5000 neurons/well. For each 48 well
plate 12 wells received no growth factor, 12 received 100
ng/ml NGF, 12 received 100 ng/ml GDNF and the
remaining 12 received 100 ng/ml BDNF. A total of 3
plates were utilized and each culture plate was generated
independently. Following 5 days of culture, RNA was
extracted from TG cultures using a ToTALLY RNA
(Ambion, Austin, TX) total RNA extraction kit and each of
the 12 wells per condition were pooled together to yield
sufficient RNA. RNA samples were subsequently treated
with DNA-free DNAse (Ambion) for removal of trace
amounts of DNA. RNA concentrations were determined
by UV absorbance, and RNA samples were then diluted to
equal concentrations in TE buffer. For realtime PCR
assessment of TRPV1 mRNA levels, samples were loaded
in triplicate in 96-well reaction plates with each sample
containing 150 ng RNA, 2X RT-PCR Taqman Master Mix,
40X Multiscribe and RNase Inhibitor solution, forward
primer (tcc agt caa gcc cca cat c), reverse primer (tcc gag tca
ccc ttc cca) and Taqman probe (6FAM tca cta cca gga gtc
gta ccc ggc ttt TAMRA) (all 300 nM, all reagents Applied
Biosystems, Foster City, CA) in a final reaction volume of
50 µL. Controls were run concomitantly using the same
reaction recipe with a rodent GAPDH control kit (Applied
Biosystems), primers and probe at 50 nM. Reactions were
run on an ABI Prism 7700 (Applied Biosystems) with an
initial RT step of 48°C for 30 min followed by a 95°C 10
min denaturation step and then a repeating denaturation,
extension cycle of 95°C for 15 s and 60°C for 1 min for
55 cycles in order to reach a full plateau for all samples.
All data were normalized to GAPDH mRNA levels to
account for any variation in RNA concentrations between
samples.
Western blotting
TG cultures were prepared on 48-well poly-D-lysine pre-
coated plates at an initial density of ~5000 neurons/well.
For each 48 well plate 12 wells received no growth factor,
12 received 100 ng/ml NGF, 12 received 100 ng/ml GDNF
and the remaining 12 received 100 ng/ml BDNF. A total
of 3 plates were utilized and each culture was generated
independently. After five days, total protein was extracted
by first lysing cells with lysis buffer (1 mM Na pyrophos-
phate, 50 mM HEPES, 1% Triton X-100, 50 mM NaCl, 50
mM NaF, 5 mM EDTA and 1 mM Na orthovanadate) sup-
plemented with 1% protease inhibitor cocktail and then
homogenizing the combined lysate from the 12 wells per
condition by pumping it through a 25 gauge needle 20
times. Extracted proteins were cleared of nuclei and cellu-
lar debris by spinning the homogenate at 1000 × g for 5
min at 4°C. Protein levels were then measured by the
Bradford method. Proteins were run at a concentration of
20 µg/lane on a 12.5% SDS-PAGE gel and transferred to
Immobilon – P membranes (Millipore). Membranes were
blocked in 5% dry milk for 1 hr and then exposed to rab-
bit anti-TRPV1 antibody (Neuromics, Minneapolis MN),
at a concentration of 1:1000, overnight at 4°C. Mem-
branes were then incubated with donkey anti-rabbit
horseradish peroxidase-linked secondary antibody
(Amersham, 1:5000) for 1 hr followed by ECL Western
blotting detection for 1 min (Amersham). Blots were next
exposed to film and subsequently scanned on a flatbed
scanner. To control for protein loading, membranes were
then stripped and reblotted for β-actin. Images were
assessed for changes in TRPV1 protein using NIH image
and normalized to β-actin protein levels.
CGRP release and CGRP content
All experiments were performed in 48-well poly-D-lysine
pre-coated plates. Data shown are representative of at least
3 independently conducted CGRP release experiments
with consistent results and neurons were plated at the
same density as indicated for survival, ICC, realtime PCR
and Western blotting experiments (~5000 neurons/well).
Culture medium was changed at 24 and 72 hr, and all
CGRP assays were performed on day 5. TG cultures were
washed free of culture medium by 2 successive washes
with release buffer (Hank's balanced salt solution (Gibco)
supplemented with 10.9 mM HEPES, 4.2 mM sodium
bicarbonate, 10 mM dextrose and 0.1% bovine serum
albumin (BSA), pH 7.4). Growth factors were not
included in the release buffer. Following washing, TG cul-
tures were exposed for 10 min to the indicated concentra-
tions of CAP, AEA or ACEA or to 50 mM K+ buffer
(containing 2.5 mM CaCl2, 50 mM KCl, 1.2 mM MgCl2,
90 mM NaCl, 25 mM NaHCO3, 1 mM NaH2PO4, 10 mM
dextrose, 15 mM Hepes, 16 uM thiophan and 0.1% BSA
at pH = 7.4), after which the CGRP-containing superna-
tant was removed and transferred to glass culture tubes
(Fisher). Content was assessed by hypotonic lysis with
deionized H2O supplemented with 1% protease inhibitor
cocktail (Sigma) for 30 min. CGRP release or content for
each well was subsequently measured by
radioimmunoassay.
CGRP radioimmunoassay
Following culture release assays, individual aliquots of the
superfusate (0.5 ml) were incubated with a C-terminally
directed anti-CGRP antiserum (kindly donated by Dr
Michael Iadarola, NIDCR, NIH, Bethesda, MD, USA).
After 24 h, 100 µL of [125I]-CGRP28–37 (approximately
20000–25000 cpm) and 50 µL of goat anti-rabbit anti-Page 12 of 15
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another 24 h, bound peptide was separated from free
peptide via immunomagnetic separation (PerSeptive Bio-
systems, Framingham, MA, USA). All incubations were
carried out at 4°C. The minimum detection limit for this
assay is approximately 1–2 fmol per tube, with 50% dis-
placement occurring at 20–40 fmol per tube. To account
for the possibility of any nonspecific effects on the RIA, all
drugs used in the release experiments were included in
separate standard curves for the purposes of data analysis.
We did not observe any alterations in the standard curve
for any of the compounds utilized in these studies
Data analysis and statistics
All data are presented as mean ± SEM unless otherwise
stated. When normalizations for CGRP release or content
to neuron numbers for either CGRP or TRPV1-immunore-
active neurons were made the equation shown in figure
11 was used. All data were analyzed using GraphPad
Prism for Mac OSX (GraphPad, San Diego, CA). To assess
statistical differences, data were analyzed by one-way
ANOVA followed by Tukey's post-test, for multiple com-
parisons, or Dunnett's post-test to compare all groups to
the control group. For differences between growth factors
at the same concentrations differences were assessed by
two-way ANOVA with Bonferroni post-test for between
group comparisons. All nonlinear regressions were fit to a
sigmoidal curve with variable slope.
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